Retatrutide: Why Is Everyone Talking About It?

Retatrutide achieves its record-breaking weight loss results through a three-pronged metabolic attack that no single or dual agonist can replicate. Understanding how each receptor contributes explains why the clinical results are so significantly ahead of earlier-generation compounds.

Prong 1: Reduce Caloric Intake (GLP-1)

The GLP-1 component suppresses appetite centrally via the hypothalamus and peripherally by delaying gastric emptying. Food stays in the stomach longer, you feel full sooner, and the drive to eat between meals is reduced. This is the same mechanism that makes semaglutide effective — but it's only one piece of retatrutide's triple mechanism.

Prong 2: Improve Metabolic Efficiency (GIP)

The GIP component enhances insulin sensitivity, improves how fat tissue metabolises energy, and amplifies the effects of GLP-1 signalling. This dual action is what gives tirzepatide its edge over semaglutide — and retatrutide includes this pathway too.

Prong 3: Increase Energy Expenditure (Glucagon)

This is retatrutide's unique advantage. The glucagon receptor activation increases the body's energy expenditure, promotes lipolysis (active fat breakdown), and enhances fatty acid oxidation in the liver. While the first two prongs reduce energy input, glucagon increases energy output — creating a more aggressive caloric deficit than dietary restriction alone.

Titration and Dosing

Clinical trials used a slow titration schedule starting at lower doses and increasing every 4 weeks to minimise gastrointestinal side effects. Phase 2 data tested doses of 1mg, 4mg, 8mg, and 12mg administered weekly via subcutaneous injection. The 8mg and 12mg doses produced the most significant weight loss.

For specific reconstitution volumes and dose-to-unit conversion tables for each vial size, see our Reconstitution Guide →